Imperial College London
Alternate

ProfessorGeorgiosKassiotis

Faculty of Medicine, Department of Infectious Disease

Professor of Retrovirology
 
 
 
//

Contact

 

g.kassiotis Website

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fendler:2021:10.1038/s43018-021-00274-w,
author = {Fendler, A and Shepherd, STC and Au, L and Wilkinson, KA and Wu, M and Byrne, F and Cerrone, M and Schmitt, AM and Joharatnam-Hogan, N and Shum, B and Tippu, Z and Rzeniewicz, K and Boos, LA and Harvey, R and Carlyle, E and Edmonds, K and Del, Rosario L and Sarker, S and Lingard, K and Mangwende, M and Holt, L and Ahmod, H and Korteweg, J and Foley, T and Bazin, J and Gordon, W and Barber, T and Emslie-Henry, A and Xie, W and Gerard, CL and Deng, D and Wall, EC and Agua-Doce, A and Namjou, S and Caidan, S and Gavrielides, M and MacRae, J and Kelly, G and Peat, K and Kelly, D and Murra, A and Kelly, K and O'Flaherty, M and Dowdie, L and Ash, N and Gronthoud, F and Shea, RL and Gardner, G and Murray, D and Kinnaird, F and Cui, W and Pascual, J and Rodney, S and Mencel, J and Curtis, O and Stephenson, C and Robinson, A and Oza, B and Farag, S and Leslie, I and Rogiers, A and Iyengar, S and Ethell, M and Messiou, C and Cunningham, D and Chau, I and Starling, N and Turner, N and Welsh, L an},
doi = {10.1038/s43018-021-00274-w},
journal = {Nature Cancer},
pages = {1305--1320},
title = {Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study},
url = {http://dx.doi.org/10.1038/s43018-021-00274-w},
volume = {2},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
AU  - Fendler,A
AU  - Shepherd,STC
AU  - Au,L
AU  - Wilkinson,KA
AU  - Wu,M
AU  - Byrne,F
AU  - Cerrone,M
AU  - Schmitt,AM
AU  - Joharatnam-Hogan,N
AU  - Shum,B
AU  - Tippu,Z
AU  - Rzeniewicz,K
AU  - Boos,LA
AU  - Harvey,R
AU  - Carlyle,E
AU  - Edmonds,K
AU  - Del,Rosario L
AU  - Sarker,S
AU  - Lingard,K
AU  - Mangwende,M
AU  - Holt,L
AU  - Ahmod,H
AU  - Korteweg,J
AU  - Foley,T
AU  - Bazin,J
AU  - Gordon,W
AU  - Barber,T
AU  - Emslie-Henry,A
AU  - Xie,W
AU  - Gerard,CL
AU  - Deng,D
AU  - Wall,EC
AU  - Agua-Doce,A
AU  - Namjou,S
AU  - Caidan,S
AU  - Gavrielides,M
AU  - MacRae,J
AU  - Kelly,G
AU  - Peat,K
AU  - Kelly,D
AU  - Murra,A
AU  - Kelly,K
AU  - O'Flaherty,M
AU  - Dowdie,L
AU  - Ash,N
AU  - Gronthoud,F
AU  - Shea,RL
AU  - Gardner,G
AU  - Murray,D
AU  - Kinnaird,F
AU  - Cui,W
AU  - Pascual,J
AU  - Rodney,S
AU  - Mencel,J
AU  - Curtis,O
AU  - Stephenson,C
AU  - Robinson,A
AU  - Oza,B
AU  - Farag,S
AU  - Leslie,I
AU  - Rogiers,A
AU  - Iyengar,S
AU  - Ethell,M
AU  - Messiou,C
AU  - Cunningham,D
AU  - Chau,I
AU  - Starling,N
AU  - Turner,N
AU  - Welsh,L
AU  - van,As N
AU  - Jones,RL
AU  - Droney,J
AU  - Banerjee,S
AU  - Tatham,KC
AU  - O'Brien,M
AU  - Harrington,K
AU  - Bhide,S
AU  - Okines,A
AU  - Reid,A
AU  - Young,K
AU  - Furness,AJS
AU  - Pickering,L
AU  - Swanton,C
AU  - Gandhi,S
AU  - Gamblin,S
AU  - Bauer,DL
AU  - Kassiotis,G
AU  - Kumar,S
AU  - Yousaf,N
AU  - Jhanji,S
AU  - Nicholson,E
AU  - Howell,M
AU  - Walker,S
AU  - Wilkinson,RJ
AU  - Larkin,J
AU  - Turajlic,S
DO  - 10.1038/s43018-021-00274-w
EP  - 1320
PY  - 2021///
SN  - 2662-1347
SP  - 1305
TI  - Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
T2  - Nature Cancer
UR  - http://dx.doi.org/10.1038/s43018-021-00274-w
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712508700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.nature.com/articles/s43018-021-00274-w#citeas
UR  - http://hdl.handle.net/10044/1/92459
VL  - 2
ER  -
Download